Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRT1419 + Sunitinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRT1419 | PRT 1419|PRT-1419 | MCL1 Inhibitor 18 | PRT1419 is an inhibitor of myeloid cell leukemia 1 (MCL1) that blocks inactivation of pro-apoptotic proteins by Mcl1, which may lead to apoptosis of tumor cells overexpressing Mcl1 (NCI Drug Dictionary). | |
Sunitinib | Sutent | SU011248 | CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 RET Inhibitor 53 VEGFR2 Inhibitor 37 | Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 loss | lung cancer | sensitive | PRT1419 + Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of PRT1419 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). | 38371625 |
PBRM1 inact mut | clear cell renal cell carcinoma | sensitive | PRT1419 + Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of PRT1419 and Sutent (sunitinib) synergistically inhibited spheroid growth of clear cell renal cell carcinoma cell lines harboring inactivating PBRM1 mutations in culture (PMID: 38371625). | 38371625 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|